CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients

References

• Weissert R. Adaptive immunity is the key to the understanding of autoimmune and paraneoplastic inflammatory central nervous system disorders. Front Immunol. 2017;8:336. doi:10.3389/fimmu.2017.0033628386263
   PubMed Web of Science ®Google Scholar
• Höftberger R. Neuroimmunology: an expanding frontier in autoimmunity. Front Immunol. 2015;6:206. doi:10.3389/fimmu.2015.0020625972873
   PubMed Web of Science ®Google Scholar
• Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77:589–593. doi:10.1212/WNL.0b013e318228c13621795662
   PubMed Web of Science ®Google Scholar
• Platt MP, Agalliu D, Cutforth T. Hello from the other side: how autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis. Front Immunol. 2017;8:442. doi:10.3389/fimmu.2017.0044228484451
   PubMed Web of Science ®Google Scholar
• Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127:701–721. doi:10.1016/j.jaci.2010.11.05021377040
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36:705–716. doi:10.1016/j.immuni.2012.05.00822633458
   PubMed Web of Science ®Google Scholar
• Kothur K, Wienholt L, Brilot F, Dale RC. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. Cytokine. 2016;77:227–237. doi:10.1016/j.cyto.2015.10.00126463515
   PubMed Web of Science ®Google Scholar
• Ai P, Zhang X, Xie Z, et al. The HMGB1 is increased in CSF of patients with an Anti-NMDAR encephalitis. Acta Neurologica Scandinavica. 2018;137:277–282. doi:10.1111/ane.1285029023630
   PubMed Web of Science ®Google Scholar
• Leypoldt F, Hoftberger R, Titulaer MJ, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurology. 2015;72:180–186. doi:10.1001/jamaneurol.2014.295625436993
   PubMed Web of Science ®Google Scholar
• Kothur K, Wienholt L, Mohammad SS, et al. Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, Anti-NMDAR and enteroviral encephalitis. PloS One. 2016;11:e0161656. doi:10.1371/journal.pone.016165627575749
   PubMed Web of Science ®Google Scholar
• Omae T, Saito Y, Tsuchie H, Ohno K, Maegaki Y, Sakuma H. Cytokine/chemokine elevation during the transition phase from HSV encephalitis to autoimmune anti-NMDA receptor encephalitis. Brain Dev. 2018;40:361–365. doi:10.1016/j.braindev.2017.12.00729277332
   PubMed Web of Science ®Google Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. doi:10.1016/S1474-4422(15)00401-926906964
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129:200–211. doi:10.1093/brain/awh68016280350
   PubMed Web of Science ®Google Scholar
• Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med. 2001;193:1373–1381. doi:10.1084/jem.193.12.137311413192
   PubMed Web of Science ®Google Scholar
• Anja L, Kinya N, Kristine M, et al. Kinetics and expression patterns of chemokine receptors in human CD4+T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Eur J Immunol. 2003;33(2):474–482. doi:10.1002/immu.20031002312645946
   PubMed Web of Science ®Google Scholar
• Olesen MN, Soelberg K, Debrabant B, et al. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. J Neuroinflammation. 2019;16:59. doi:10.1186/s12974-019-1440-530857557
   PubMed Web of Science ®Google Scholar
• Markowicz M, Schotta AM, Kundi M, et al. CXCL13 concentrations in cerebrospinal fluid of patients with lyme neuroborreliosis and other neurological disorders determined by luminex and ELISA. Ticks Tick Borne Dis. 2018;9:1137–1142. doi:10.1016/j.ttbdis.2018.04.00829705691
   PubMed Web of Science ®Google Scholar
• Wagner JN, Weis S, Kubasta C, Panholzer J, von Oertzen TJ. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients. Journal of Neurology. 2018;265:74–81. doi:10.1007/s00415-017-8669-7
   PubMed Web of Science ®Google Scholar
• Liba Z, Kayserova J, Elisak M, et al. Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. J Neuroinflammation. 2016;13:55. doi:10.1186/s12974-016-0507-926941012
   PubMed Web of Science ®Google Scholar
• Fujimori J, Nakashima I, Kuroda H, Fujihara K, Aoki M. Cerebrospinal fluid CXCL13 is a prognostic marker for aseptic meningitis. Journal of Neuroimmunology. 2014;273:77–84. doi:10.1016/j.jneuroim.2014.05.00824907903
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012;9:93. doi:10.1186/1742-2094-9-9322591862
   PubMed Web of Science ®Google Scholar
• Byun JI, Lee ST, Moon J, et al. Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis. Journal of Neuroimmunology. 2016;297:141–147. doi:10.1016/j.jneuroim.2016.05.02327397087
   PubMed Web of Science ®Google Scholar
• Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135:1622–1638. doi:10.1093/brain/aws08222539258
   PubMed Web of Science ®Google Scholar
• Ulusoy C, Tuzun E, Kurtuncu M, Turkoglu R, Akman-Demir G, Eraksoy M. Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders. Int J Neurosci. 2012;122:284–289. doi:10.3109/00207454.2011.64876222176581
   PubMed Web of Science ®Google Scholar
• Hermetter C, Fazekas F, Hochmeister S. Systematic review: syndromes, early diagnosis, and treatment in autoimmune encephalitis. Front Neurol. 2018;9:706. doi:10.3389/fneur.2018.0070630233481
   PubMed Web of Science ®Google Scholar
• Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94–114. doi:10.1111/nyas.1255325315420
   PubMed Web of Science ®Google Scholar
• Newman MP, Blum S, Wong RC, et al. Autoimmune encephalitis. Intern Med J. 2016;46:148–157. doi:10.1111/imj.1297426899887
   PubMed Web of Science ®Google Scholar